CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Jin Li,Yuxian Bai,Qingshan Li,Youen Lin,Hao Jiang,Zhendong Chen,Rong Huang,Na Li,Yanxia Ji,Shujun Yang,Wensheng Qiu,Bo Liu,Jufeng Wang,Kangsheng Gu,Jie Fu,Bo Wang,Jin Hu,Yan Xu,Qingmei Shi,Jianxin Yang

CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

2021

Jin Li
Yuxian Bai
Qingshan Li
Youen Lin
Hao Jiang
Zhendong Chen
Rong Huang
Na Li
Yanxia Ji
Shujun Yang
Wensheng Qiu
Bo Liu
Jufeng Wang
Kangsheng Gu
Jie Fu
Bo Wang
Jin Hu
Yan Xu
Qingmei Shi
Jianxin Yang

TPS255Background: ESCC is the predominant histological subtype of esophageal cancer, particularly in Asian countries. Platinum-based chemotherapy is the first-line standard therapy for patients wit...

Keywords:

Cisplatin
locally advanced
Oncology
Internal medicine
anti pd 1
Chemotherapy
Fluorouracil
Medicine
Esophageal cancer
Antibody
Placebo

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations